An interventional study of Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia) and Usual care, after system-side dissemination of HOAP in Diabetes, sponsored by Kaiser Permanente. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Kaiser Permanente · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Diabetes Mellitus by Kaiser Permanente — 2 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Kaiser Permanente.
Among the 26 studies in Diabetes Mellitus by Kaiser Permanente, this one is the 11th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 23 with no phase, and was the 24th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 26 studies in Diabetes Mellitus by Kaiser Permanente are open now, in 1 country. Recruiting first, the newest first:
Kaiser Permanente
Ages 18+
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 250 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 195 across the 23 interventional studies, 8,198 across the 3 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Kaiser Permanente is the lead sponsor of 393 studies on the registry; 43 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
2 of the studies in Diabetes Mellitus by Kaiser Permanente that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06746714Kaiser PermanenteHypoglycemia Prevention in High-Risk Type 2 Diabetes Patients | 2027-03-31 |
| NCT07709117Kaiser PermanenteA Pilot Study to Improve Diabetes Management Through Family-Based Health Care Navigation | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Diabetes Mellitus by Kaiser Permanente, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Severe low blood sugar (hypoglycemia) is a serious problem for people with diabetes. It can lead to dangerous falls, heart problems, memory issues, and even death. However, many healthcare providers don't recognize or manage this problem well. The investigators believe that creating a clear set of guidelines for preventing hypoglycemia, along with having a clinical pharmacist actively help high-risk patients, can make diabetes treatment safer.
In this study, the investigators developed a simple, evidence-based guide called "Hypoglycemia on a Page" (HOAP) to prevent low blood sugars. The investigators then tested it by comparing two groups of patients with type 2 diabetes who are at high risk for hypoglycemia. One group received active support from a clinical pharmacist using the HOAP guidelines, while the other group received standard care.
The main goal of this study is to see if the pharmacist's support leads to safer diabetes treatment. The investigators will also look at other factors, such as whether patients are prescribed glucagon (a medicine for severe low blood sugar), if they use continuous glucose monitoring, and whether they have worse blood sugar control or end up in the hospital for hypoglycemia. This trial aims to improve patient safety, health outcomes, and possibly lower healthcare costs.
The primary research question is whether using a "Hypoglycemia Champion" (HC) to target high risk patients with type 2 diabetes (T2D) is a feasible and effective model of care to reduce hypoglycemia risk in this population.
The goals of this study are to:
Conduct a pragmatic, randomized trial of the proactive HC intervention vs. usual care on diabetes regimen safety among KPNC members at high risk of hypoglycemia. The investigators hypothesize that at 6 months, high-risk members assigned to the HC intervention will be prescribed safer diabetes regimens (defined as discontinuation of sulfonylureas and/or rapid-/short-acting or mixed insulins) compared to usual care.
The study design will include: 1) Engaging expert clinical stakeholders and experienced KP guideline developers to create an evidence-based hypoglycemia prevention algorithm (HOAP) analogous to KPNC's successful "PHASE on a Page" guideline for cardiovascular risk management; 2) Crafting a population-based workflow protocol for proactive outreach by the HC (specifically trained clinical pharmacist) to apply this new guideline to high-risk members; and 3) Performing a pragmatic randomized trial comparing proximal clinical outcomes (diabetes medication changes) available directly from the EHR between the intervention arm (pro-active outreach by the HC) vs. controls (usual care, including availability of the HOAP). The primary analysis will be intent-to-treat and will assess differences in the proportion of patients using safer diabetes regimens (relative to their baseline regimen) between study arms. The investigators will also examine heterogeneity of treatment effects by age, race/ethnicity, and prior severe hypoglycemia events. Deliverables include: 1) Inter-regional dissemination of the HOAP algorithm and the HC workflow protocol, 2) High quality, pragmatic RCT results to inform operational decision-making, and 3) Presentations and manuscripts to further disseminate findings. This study is highly relevant to TPMG and KP because: 1) Hypoglycemia is common, morbid, and costly, 2) Providers are challenged to address the competing demands of prescribing diabetes medications to meet glycemic targets while avoiding iatrogenic hypoglycemia, 3) No regional strategies currently exist to reduce hypoglycemia risk. This work has strategic implications for our organization because a new HEDIS measure proposed for measurement year 2023 will assess emergency department admissions for hypoglycemia in older adults with diabetes. The proposal will address this gap in organizational clinical care by developing and evaluating a practical, proactive, population management approach to hypoglycemia prevention for members with T2D at high risk of hypoglycemia.
The criteria were revised on the registry on Oct 14, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Aim 4: In addition to criteria above, participants will only include patients with type 2 diabetes (T2D) who use a CGM device, have authorized sharing of their CGM data with their healthcare provider and have evidence of "excess hypoglycemia" (>=4% TBR on continuous glucose monitor readouts).
Intervention group, receiving protocol-driven outreach by a clinical pharmacist (the "hypoglycemia champion", or HC) to hypoglycemia-prone patients with T2D
Behavioral: Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia)
Usual care, after system-wide dissemination of HOAP
Behavioral: Usual care, after system-side dissemination of HOAP
The Hypoglycemia Champion (HC) pharmacist reviewed patient charts before conducting proactive outreach. They did not contact subjects with active psychiatric issues or those admitted to a skilled nursing facility. The patient's care team (PCP and APM) were also contacted for peer consent. The outreach process involved an initial phone call with a secure electronic message or mailed letter (for those without secure KPNC patient portal access) if the initial call was unsuccessful. A second and third phone call attempt was made for non-responders.
Patients had their diabetes treated as usual by their diabetes care provider or primary care physician, after system-wide dissemination of HOAP.
Number of patients with sulfonylureas, mealtime, or mixed insulin discontinued
We will test for differences in the proportion of patients prescribed safer diabetes regimens (i.e., discontinuation of sulfonylureas, mealtime or mixed insulin)
Time frame: 6 months
Proportion of patient with "excess hypoglycemia"
Proportion of patients with "excess hypoglycemia" (\>=4% TBR on continuous glucose monitor readouts) who achieve "acceptable levels of hypoglycemia" (\<4% TBR on continuous glucose monitor readouts), comparing study participants (augmented usual care) to data-only patients (usual care controls).
Time frame: 6 months
Number of participants prescribed CGM
The study will test for differences in the proportion of patients prescribed CGM
Time frame: 6 months
Number of participants prescribed glucagon
The study will test for differences in the proportion of patients prescribed glucagon
Time frame: 3, 6, 12 months
Number of participants with A1c <8%
The study will test for differences in the proportion of patients with good glycemic control (A1c \<8%)
Time frame: 3, 6, 12 months
Number of participants with ED visit or hospitalization for hypoglycemia
The study will test for differences in the proportion of patients who had an ED visit or hospitalization for hypoglycemia
Time frame: 6 months
Percentage of patients who achieve "acceptable levels of hypoglycemia"
Examine differences between study participants and data-only patients in the percentage of patients who achieve "acceptable levels of hypoglycemia"
Time frame: 6 and 12 months
Number of study PharmD visits
The study will examine the differences between participant arms for the number of PharmD visits.
Time frame: 3, 6, 12 months
Diabetes Focused visits
The study will examine the differences between participant arms for the number of diabetes focused visits.
Time frame: 3, 6, 12 months
Changes in insulin regimens
The study will examine the differences between participant arms for the changes in insulin regimens.
Time frame: 3, 6, 12 months
Hypoglycemia on the problem list
The study will examine the differences between participant arms for the presence of 'hypoglycemia' on the problem list.
Time frame: 3, 6, 12 months
ED visits/ hospitalizations (any cause)
The study will examine the differences between participant arms for number of ED visits or hospitalizations, for any cause.
Time frame: 3, 6, 12 months
Plan to share: No — The data generated and/or analyzed by the described study are not publicly available due to institutional policies but are available from the corresponding author on reasonable request and with the appropriate IRB approvals.
Started Jul 2023 (actual). Primary completion is estimated for Mar 2027, 44 months after the start.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 44 months is above that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jul 2024 → Mar 2027 and completion Dec 2024 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.